Orphan drug designation for NTZ expanded.
D017088:AIDS-Related Opportunistic Infections / Q000188:drug therapy*; D000975:Antioxidants / Q000627:therapeutic use*; D017321:Clinical Trials, Phase I as Topic; D017322:Clinical Trials, Phase II as Topic; D003457:Cryptosporidiosis / Q000188:drug therapy*; D017277:Drug Approval; D006801:Humans; D016867:Immunocompromised Host; D009574:Nitro Compounds; D013844:Thiazoles / Q000627:therapeutic use*; D014481:United States; D014486:United States Food and Drug Administration
D000975:Antioxidants; D009574:Nitro Compounds; D013844:Thiazoles; C041747:nitazoxanide